MKC-3946 exerted modest cytotoxicity toward multiple myeloma cells under in vitro conditions, but significantly suppressed the growth of subcutaneous myeloma in mice by inhibiting XBP1 splicing and enhancing the apoptotic effects of the anti-cancer drugs bortezomib and 17-AAG [207]. Here, XBP1 is linked to plasma cell myeloma.